Correction to: Efficacy and Pharmacodynamic Target Attainment for Ceftazidime–Avibactam Off-Label Dose Regimens in Patients with Continuous or Intermittent Venovenous Hemodialysis: Two Case Reports (Infectious Diseases and Therapy, (2022), 11, 6, (2311-2319), 10.1007/s40121-022-00621-z)

doi:10.1007/s40121-022-00675-z

科研成果详情

名称	Correction to: Efficacy and Pharmacodynamic Target Attainment for Ceftazidime–Avibactam Off-Label Dose Regimens in Patients with Continuous or Intermittent Venovenous Hemodialysis: Two Case Reports (Infectious Diseases and Therapy, (2022), 11, 6, (2311-2319), 10.1007/s40121-022-00621-z)
作者	Zhang, Xiao-Shan1,2; Wang, Yu-Zhen 1,2; Shi, Da-Wei1; Xu, Fang-Min 1,2; Yu, Jun-Hui 1,2; Chen, Jie 3; Lin, Guan-Yang1; Zhang, Chun-Hong 1; Yu, Xu-Ben1; Tang, Cong-Rong1
发表期刊	Infectious Diseases and Therapy;
语种	英语
原始文献类型	Erratum
摘要	In the original publication of the article, there should be three corresponding authors; Chun-Hong Zhang, Xu-Ben Yu and Cong-Rong Tang This has been corrected in this paper.
出版者	SPRINGER LONDON LTD
ISSN	2193-8229
EISSN	2193-6382
卷号	11
期号	6
页码	2321-2321
DOI	10.1007/s40121-022-00675-z
页数	1
WOS类目	Infectious Diseases
WOS研究方向	Infectious Diseases
WOS记录号	WOS:000878925200001
收录类别	SCOPUS ; SCIE
发布日期	2022-12-01
URL	查看原文
PubMed ID	36333476
通讯作者地址	[Zhang, Chun-Hong;Yu, Xu-Ben;Tang, Cong-Rong]Wenzhou Med Univ, Affiliated Hosp 1, Dept Pharm, Wenzhou, Peoples R China.
Scopus学科分类	Microbiology (medical);Infectious Diseases
SCOPUSEID	SCOPUS_ID:85141344104
引用统计
文献类型	其他
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/184793
专题	附属第一医院药学院（分析测试中心）_药学系
通讯作者	Zhang, Chun-Hong; Yu, Xu-Ben; Tang, Cong-Rong
作者单位	1.Wenzhou Med Univ, Affiliated Hosp 1, Dept Pharm, Wenzhou, Peoples R China; 2.Wenzhou Med Univ, Dept Pharm, Wenzhou, Peoples R China; 3.Wenzhou Med Univ, Affiliated Hosp 1, Intens Care Unit, Wenzhou, Peoples R China
第一作者单位	附属第一医院; 药学部药学部; 药学系
通讯作者单位	附属第一医院; 药学部药学部
推荐引用方式 GB/T 7714	Zhang, Xiao-Shan,Wang, Yu-Zhen,Shi, Da-Wei,et al. Correction to: Efficacy and Pharmacodynamic Target Attainment for Ceftazidime–Avibactam Off-Label Dose Regimens in Patients with Continuous or Intermittent Venovenous Hemodialysis: Two Case Reports (Infectious Diseases and Therapy, (2022), 11, 6, (2311-2319), 10.1007/s40121-022-00621-z). 2022.